Literature DB >> 35390316

Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction.

Xinyi Zhang1, Shidan Wang1, Erin R Rudzinski2, Saloni Agarwal3, Ruichen Rong1, Donald A Barkauskas4, Ovidiu Daescu3, Lauren Furman Cline5, Rajkumar Venkatramani6, Yang Xie7, Guanghua Xiao8, Patrick Leavey9.   

Abstract

Rhabdomyosarcoma (RMS), the most common malignant soft tissue tumor in children, has several histologic subtypes that influence treatment and predict patient outcomes. Assistance with histologic classification for pathologists as well as discovery of optimized predictive biomarkers is needed. A convolutional neural network for RMS histology subtype classification was developed using digitized pathology images from 80 patients collected at time of diagnosis. A subsequent embryonal rhabdomyosarcoma (eRMS) prognostic model was also developed in a cohort of 60 eRMS patients. The RMS classification model reached a performance of an area under the receiver operating curve of 0.94 for alveolar rhabdomyosarcoma and an area under the receiver operating curve of 0.92 for eRMS at slide level in the test data set (n = 192). The eRMS prognosis model separated the patients into predicted high- and low-risk groups with significantly different event-free survival outcome (likelihood ratio test; P = 0.02) in the test data set (n = 136). The predicted risk group is significantly associated with patient event-free survival outcome after adjusting for patient age and sex (predicted high- versus low-risk group hazard ratio, 4.64; 95% CI, 1.05-20.57; P = 0.04). This is the first comprehensive study to develop computational algorithms for subtype classification and prognosis prediction for RMS histopathology images. Such models can aid pathology evaluation and provide additional parameters for risk stratification.
Copyright © 2022 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35390316      PMCID: PMC9194647          DOI: 10.1016/j.ajpath.2022.03.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  20 in total

1.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

Authors:  Daniel Williamson; Edoardo Missiaglia; Aurélien de Reyniès; Gaëlle Pierron; Benedicte Thuille; Gilles Palenzuela; Khin Thway; Daniel Orbach; Marick Laé; Paul Fréneaux; Kathy Pritchard-Jones; Odile Oberlin; Janet Shipley; Olivier Delattre
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

Review 2.  Deep learning.

Authors:  Yann LeCun; Yoshua Bengio; Geoffrey Hinton
Journal:  Nature       Date:  2015-05-28       Impact factor: 49.962

Review 3.  A survey on deep learning in medical image analysis.

Authors:  Geert Litjens; Thijs Kooi; Babak Ehteshami Bejnordi; Arnaud Arindra Adiyoso Setio; Francesco Ciompi; Mohsen Ghafoorian; Jeroen A W M van der Laak; Bram van Ginneken; Clara I Sánchez
Journal:  Med Image Anal       Date:  2017-07-26       Impact factor: 8.545

4.  Transfer learning on fused multiparametric MR images for classifying histopathological subtypes of rhabdomyosarcoma.

Authors:  Imon Banerjee; Alexis Crawley; Mythili Bhethanabotla; Heike E Daldrup-Link; Daniel L Rubin
Journal:  Comput Med Imaging Graph       Date:  2017-05-05       Impact factor: 4.790

5.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

6.  Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis--an Intergroup Rhabdomyosarcoma study.

Authors:  R Kodet; W A Newton; A B Hamoudi; L Asmar; M D Wharam; H M Maurer
Journal:  Med Pediatr Oncol       Date:  1997-07

7.  PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Authors:  Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

8.  Rhabdomyosarcoma. A new classification scheme related to prognosis.

Authors:  M Tsokos; B L Webber; D M Parham; R A Wesley; A Miser; J S Miser; E Etcubanas; T Kinsella; J Grayson; E Glatstein
Journal:  Arch Pathol Lab Med       Date:  1992-08       Impact factor: 5.534

Review 9.  Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Authors:  Erin R Rudzinski; Anna Kelsey; Christian Vokuhl; Corinne M Linardic; Janet Shipley; Simone Hettmer; Ewa Koscielniak; Douglas S Hawkins; Gianni Bisogno
Journal:  Pediatr Blood Cancer       Date:  2020-12-11       Impact factor: 3.167

10.  The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Archana Shenoy; Elysia Alvarez; Yueh-Yun Chi; Minjie Li; Jack F Shern; Javed Khan; Susan M Hiniker; Candace F Granberg; Douglas S Hawkins; David M Parham; Lisa A Teot; Erin R Rudzinski
Journal:  Eur J Cancer       Date:  2020-12-07       Impact factor: 9.162

View more
  1 in total

1.  Identification of Diagnostic Genes and Effective Drugs Associated with Osteoporosis Treatment by Single-Cell RNA-Seq Analysis and Network Pharmacology.

Authors:  Zhanyue Zhang; Tingbao Zhang; Liangshuang Zhou; Jianzhong Guan
Journal:  Mediators Inflamm       Date:  2022-09-25       Impact factor: 4.529

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.